SLC5A2 and hydrops fetalis: It is unclear if these benefits in AHF are mediated by a diuretic role for SGLT2 inhibitors; in an analysis of the EMPEROR-Reduced trial, empagliflozin reduced the combined risk of CV mortality or hospitalization for HF in patients with and without recent volume overload (i.e., 4 weeks before enrollment) with no difference between the groups [25].